Drug and Device Product Liability Litigation Strategy

Mark Herrmann is Vice President and Chief Counsel - Litigation at Aon Corporation, which is the world's leading insurance and reinsurance broker. Before joining Aon, he was a partner at Jones Day, where his practice focused on the defense of class action and mass tort litigation, including pharmaceutical and medical device cases. He clerked for Judge Dorothy W. Nelson of the United States Court of Appeals for the Ninth Circuit and graduated from The University of Michigan Law School (J.D. 1983) and Princeton University (A.B. 1979).David B. Alden is a partner in Jones Day's Cleveland office, where his practice focuses on products liability litigation, including pharmaceutical and medical device cases; securities and accounting fraud litigation; and issues relating to the attorney-client privilege and work product protection.Geoffrey M. Drake is a partner in King and Spalding's Tort Litigation and Environmental Group, where he represents companies in high-exposure product liability, personal injury, toxic tort, commercial and whistleblower litigation, as well as internal and external government investigations. He is also a member of the Next Generation Advisory Board for Emory University's Institute for Complex Litigation and Mass Claims.

• 1: Introduction 2: The FDA's Regulation of Prescription Drugs and Devices 3: Pre-litigation Counseling 4: Legal Issues & Theories 5: Consolidated Proceedings 6: Aggregated Proceedings - Class Actions 7: Aggregated Proceedings - Multidistrict Litigation 8: Fact Discovery 9: Expert Retention and Discovery 10: Expert Testimony, Rule 702, And Daubert 11: Preemption 12: The Learned Intermediary Doctrine 13: Motions In Limine 14: Jury Selection 15: The Trial Of A Drug Or Device Case Index